Who are Voriconazole preemptive genotyping strategy's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/voriconazole-preemptive-genotyping-strategy.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Voriconazole preemptive genotyping strategy — Competitive Intelligence Brief

Voriconazole preemptive genotyping strategy (Voriconazole preemptive genotyping strategy) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Triazole antifungal with pharmacogenomic optimization. Area: Infectious Disease.

marketed Triazole antifungal with pharmacogenomic optimization CYP2C19 enzyme (pharmacogenomic target); fungal lanosterol 14α-demethylase (therapeutic target) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Voriconazole preemptive genotyping strategy (Voriconazole preemptive genotyping strategy) — Instituto de Investigación Hospital Universitario La Paz. A pharmacogenomic strategy that uses CYP2C19 genotyping to optimize voriconazole dosing and reduce adverse events in individual patients.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Voriconazole preemptive genotyping strategy TARGET	Voriconazole preemptive genotyping strategy	Instituto de Investigación Hospital Universitario La Paz	marketed	Triazole antifungal with pharmacogenomic optimization	CYP2C19 enzyme (pharmacogenomic target); fungal lanosterol 14α-demethylase (therapeutic target)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Triazole antifungal with pharmacogenomic optimization class)

Instituto de Investigación Hospital Universitario La Paz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Voriconazole preemptive genotyping strategy — Competitive Intelligence Brief. https://druglandscape.com/ci/voriconazole-preemptive-genotyping-strategy. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab